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REVIEW
Abstract: Aprepitant, a selective high-afﬁ  nity antagonist of human substance P/neurokinin 1 
(NK1) receptors, is the active ingredient of EMEND
® which
 has recently been approved by the 
FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant 
undergoes extensive metabolism, primarily via CYP3A4 mediated oxidation. It is eliminated 
primarily by metabolism and is not renally excreted. The apparent terminal half-life in humans 
ranged from 9 to 13 hours. Early development studies led to the development of a nanoparticle 
formulation to enhance exposure and minimize food effects. Two large randomized trials 
accruing 1099 patients studied the effect in patients receiving cisplatin of adding aprepitant to 
ondansetron and dexamethasone on day 1 then to dexamethasone on days 2 and 3 to control 
delayed emesis. The complete response of no vomiting and no rescue medication overall from 
days 1 to 5 improved from 48% to 68% (p<0.001), a 13% improvement in acute emesis but 
a 21% improvement in delayed emesis with the improvement from 51% to 72% (p<0.001). 
Similarly, 866 patients treated with cyclophosphamide plus either doxorubicin or epirubicin, 
received either ondansetron, dexamethasone, and aprepitant on day 1 followed by aprepitant on 
days 2 and 3 or ondansetron and dexamethasone on day 1 and dexamethasone on days 2 and 3. 
The overall complete response rate over 5 days was better for the aprepitant group 50.8% vs 
42.5% (p=0.015). Complete responses were reported in more patients taking aprepitant in both 
the acute (76% vs 69%, p=0.034) and delayed (55% vs 49%, p=0.064) phases of vomiting. 
There were no clinically relevant differences in toxicity by adding aprepitant and improvements 
in the quality of life of patients on chemotherapy were recorded.
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Introduction
Cytotoxic chemotherapy drugs can cause acute nausea and vomiting in the ﬁ  rst 24 
hours, and then delayed emesis between 2 and 6 days. Cisplatin is the example of a drug 
with high emetic potential, which means that 90% or more of patients will vomit if they 
don’t receive prophylactic antiemetics. Cisplatin is often used to test the efﬁ  cacy of 
new antiemetic agents. Antiemetics are best given prior to the initial course of therapy 
because patients who vomit after chemotherapy can develop anticipatory emesis prior 
to subsequent cycles of chemotherapy (Antiemetic Subcommittee MASCC 1998).
The understanding of the role of the 5 hydroxytryptamine3 receptors, predominantly 
in the small bowel, as the mediators of acute cytotoxic induced emesis led to a major 
breakthrough in the control of chemotherapy-induced emesis with the introduction of 
the 5 hydroxytrytamine3 antagonist, ondansetron, which revolutionized the treatment 
of acute post-chemotherapy emesis. Ondansetron in combination with dexamethasone 
controlled acute cisplatin induced emesis in over 80% patients but control of the 
delayed emesis only approached 50% (Roila et al 1996). However, after the introduction 
of the 5HT3 antagonists patients were still listing nausea and vomiting in their top 
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three side-effects (de Boer-Dennert et al 1997). Clinicians 
underestimate the incidence of delayed emesis by up to 30% 
(Grunberg et al 2004). 
Nanoparticle formulation 
development
Early preclinical studies showed less than dose proportional 
increases in systemic exposure in Beagle dogs at oral 
doses of 2 and 32  mg/kg with suspensions of micronized 
aprepitant (mean size 5 microns). A similar dose–exposure 
relationship was observed in early clinical studies using tablet 
formulations made of micronized bulk drug. In addition, 
a signiﬁ  cant, positive food effect on absorption was seen 
in healthy, young, male volunteers who had been given a 
high fat breakfast prior to dosing. These early clinical data 
suggested that the projected efﬁ  cacious human dose would 
be relatively high and development of a more bioavailable 
formulation could potentially reduce the dose. Formulation 
efforts to develop a more bioavailable formulation that 
eliminates/minimizes food effect on absorption were crucial 
for the future of the program. 
Aprepitant is a basic compound with a pKa value of 9.7 
within the pH range from 2 to 12 (Figure 1). It is a white to 
off-white, crystalline, non-hygroscopic solid with a melting 
point of 254°C. Early salt form screening was conducted 
but all salts examined showed rapid disproportionation 
in water and poor chemical stability. The free base form 
of the molecule was chosen for development based on 
superior physicochemical properties. The free base aqueous 
solubility (3–7 μg/ml) is very low in the pH range of 2–10, 
and increases to 0.13 mg/mL at pH 1.0. The compound has 
a log P value of 4.8 at pH 7.0, suggesting a relatively high 
lipophilicity, the potential for dietary fat and bile to solubilize 
the drug in vivo, and potentially reasonable permeability. 
Particle size reduction methodologies could increase the 
available surface area to enhance the rate of solubilization 
and thereby increase exposure. Preclinical studies in dogs 
were conducted to examine the relationship between particle 
size and exposure.
In vivo dog studies of suspensions of aprepitant 
indicated a 3x increase in exposure as the particle size was 
reduced from 5 microns to less than 150 nanometers. In 
the nanomilling process, the slurry of drug particles in an 
aqueous polymeric solution is recirculated through a stirred 
media mill ﬁ  lled with polymeric media. The energy imparted 
by colliding media results in breakage of drug particles. The 
recirculation process is continued until the desired drug 
particle size is achieved. The resulting colloidal dispersion 
of nanometer drug particles is then converted into a solid-
dosage form and then processed to form a tablet or a capsule 
dosage form (Figure 2).
Solid dosage form process optimization was based on 
bioavailability, processing, and capabilities of the two lead 
processes. The column-coating processed formulations had 
marginally higher exposure compared with a spray-dried 
processed formulations. The spray-drying process produced 
a hygroscopic powder due to the formation of amorphous 
sucrose, one of the key ingredients in the formulation. 
In addition, the spray-dried powder may require further 
agglomeration processing to enhance its ﬂ  ow characteristics 
Figure 2  Aprepitant nanomilling ﬂ  ow schematic.
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Figure 1  Aprepitant’s active chemical structure.
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and the effect of manufacturing scale on the physical 
properties of the spray dried powder would need to be 
investigated. Column-coated beads, on the other hand, had 
good ﬂ  ow characteristics due to their large size (greater 
than the substrate mean size of 600 μm) and nearly spherical 
shape. The column-coated beads size would remain the same 
with scale up since the weight gain (or the composition) 
would remain the same. Hence, the aprepitant redispersion 
characteristics of the coated beads would be independent 
of column coating scale. Both processes have comparable 
processing time, but the spray drying process is a semi-
continuous process compared with batch processing with 
the column coating process. Based on these considerations, 
the column-coating-processed formulation was chosen as the 
lead for further investigation in human clinical studies. The 
column coating process produced drug-coated beads which 
are lubricated with 1% sodium lauryl sulfate and ﬁ  lled into 
gelatin capsules. The coating contains drug-to-sucrose ratio 
of 1:1, drug-to-hydroxypropyl cellulose (HPC)-SL ratio of 
5:1, and coat weight gain of 100 weight percent. 
The inﬂ  uence of drug particle size on bioavailability 
in humans was investigated at a 100-mg dose. The human 
clinical studies conﬁ  rmed the 3–4x increase in bioavailability 
with the nanoparticle formulation compared with the alpine 
milled (mean 5 micron) drug formulation. In addition, the 
food effect at 100-mg dose was minimal with the nanoparticle 
formulation (approximately 40%) compared with the 3–4x 
food effect observed with the 5 micron drug formulation. 
Nanoparticle formulation development focuses on 
established polymeric stabilizers to maintain size reductions. 
The addition of other surface active agents, sodium lauryl 
sulfate, provides viscosity reduction to increase process 
efﬁ  ciencies. Redispersants are needed to further stabilize 
nanoparticle colloidal suspensions to drying and freezing. 
Processing of the dried material into a ﬁ  nal dosage form 
is driven by gains in yields and dosage form elegance. 
Nanoparticle formulations provide possibilities to decrease 
food effects and dosage form potency to further beneﬁ  t patients.
Clinical trials with cisplatin 
When the ﬁ  rst of the neurokinin1 (NK1) receptor antagonists, 
aprepitant, was introduced it improved the control of acute 
emesis when added to ondansetron and dexamethasone but 
its most dramatic effects were seen in the delayed phase 
of cisplatin-induced emesis. Subsequently it was tested 
with the combination of an anthracycline and doxorubicin 
(Table1 ).
Two large randomized trials, one in South America and the 
other in Europe, North America, and Australia randomized a 
total of 1099 patients to study the effect of adding aprepitant 
to ondansetron and dexamethasone (Hesketh et al 2003; Poli-
Bigelli et al 2003). Both studied patients receiving their ﬁ  rst 
ever cycles of high-dose cisplatin speciﬁ  ed as >  70  mg/m
2 
over ≤3 hours. The patients on the control arms of both 
studies received intravenous ondansetron 32 mg 30 minutes 
before cisplatin and oral dexamethasone 20  mg on day 1 
followed by oral dexamethasone 8 mg twice daily from days 
2 to 4. The arms where aprepitant was added received oral 
aprepitant 125 mg one hour before cisplatin, then intravenous 
ondansetron 32  mg 30 minutes before cisplatin, with oral 
dexamethasone 12 mg on day 1, oral aprepitant 80 mg and 
oral dexamethasone 8 mg once daily on days 2 and 3, and on 
day 4 one dose of oral dexamethasone 8mg. 
The complete response of no vomiting and no rescue 
medication overall from days 1 to 5 improved from 48 to 
68% (p<0.001), a 13% improvement in acute emesis but a 
21% improvement in delayed emesis with the improvement 
from 51% to 72% (p<0.001). 
The overall complete response rate (CR) of no emesis in 
the South American trial was 62.7% for the aprepitant group 
Table 1  Key randomized studies with aprepitant
 Poli-Bigelli
 et al 2003  Hesketh et al 2003  Warr et al 2005
No. patients   569   530   866
Chemotherapy   Cisplatin  Cisplatin  Anthr + Cyclo
CR rates   NK1 vs control   NK1 vs control   NK1 vs control 
Acute vomiting %   82.8      68.4   89.2      78.1   88      77
(Day 1)
Delayed vomiting %   67.7      46.8   74.4      55.8   81      69
(Days 2–5)
Overall control %  62.7      43.3   72.7      52.3   51      42
(Days 1–5)
Abbreviations: Anthr, anthracycline; Cyclo, cyclophosphamide; NK1, neurokinin1receptor.International Journal of Nanomedicine 2007:2(1) 16
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vs 43.3% for the control (p<0.001). In the international trial 
the CR rate was 72.7% for the aprepitant arm and 52.3% for 
the control arm (p<0.001). For acute emesis the CR rates were 
82.8% vs 68.4% (p<0.001) and 89.2% vs 78.1% respectively, 
favoring the aprepitant groups. In the delayed phase of emesis 
the difference between the groups was greater, 67.7% vs 
46.8% (p<0.001) in the South American study and 74.4% vs 
55.8% (p<0.001) in the international trial. The differences 
achieved by aprepitant were sustained over the 5 days post 
chemotherapy. As has been previously reported in other 
studies, the control of vomiting was superior to the control 
of nausea. The efﬁ  cacy of the triple antiemetic therapy 
(ondansetron, dexamethasone, and aprepitant) persisted over 
6 courses of chemotherapy. No differences in response rates 
were found in different age groups in both the acute and 
delayed phases of emesis and the improvement of the quality 
of life was similar for older and younger patients. 
Given that it had been common practice to continue 
the 5HT3 receptor antagonist with dexamethasone into 
the delayed phase of emesis, a subsequent reported study 
randomized 489 patients receiving high dose cisplatin to 
either a control arm of ondansetron and dexamethasone 
for 4 days or aprepitant, ondansetron, and dexamethasone 
only on day 1 post chemotherapy followed by aprepitant 
and dexamethasone on days 2–3 and dexamethasone alone 
on day 4 (Aapro et al 2005). During the ﬁ  rst 5 days post 
chemotherapy, the 3-day aprepitant regimen provided a 
superior complete response rate (72% vs 61%, p=0.003). 
Compared with a regimen using 4 days of ondansetron, 
the regimen using 3 days of aprepitant provided a 9% 
improvement in protection from nausea and vomiting on 
day 1 (88% vs 79%, p=0.005) and an 11% improvement on 
days 2 through 5 (74% vs. 63%, p=0.004). Again there was 
no signiﬁ  cant difference in toxicity between the arms. 
Clinical trials with 
cyclophosphamide and an 
anthracycline
In a study exploring the use of aprepitant with regimens which 
do not contain cisplatin, and arguably cause more moderate 
emesis, 866 patients treated with cyclophosphamide plus 
either doxorubicin or epirubicin, received either ondansetron, 
dexamethasone, and aprepitant on day 1 followed by 
aprepitant on days 2 and 3 or ondansetron and dexamethasone 
on day 1 and ondansetron days 2 and 3 (Warr et al 2005). All 
agents were given orally in this study. The overall complete 
response rate over 5 days was better for the aprepitant 
group 50.8% vs 42.5% (p=0.015). Complete responses were 
reported in more patients taking aprepitant in both the acute 
(76% vs 69%, p=0.034) and delayed (55% vs 49%, p=0.064) 
phases of vomiting although the delayed phase difference 
did not reach statistical signiﬁ  cance because nausea was not 
as well controlled as vomiting in this phase. No differences 
were seen between the groups in the use of rescue medication, 
which suggests that nausea was not as well controlled as 
vomiting. The question remains of whether these results 
could have been improved by adding dexamethasone in the 
delayed phase of emesis.
The improvement in efficacy in the aprepitant arm 
was demonstrated over 4 cycles of chemotherapy with the 
complete response rates in comparison with the control arm 
being 53.8% vs. 39.4% in cycle 2, 54.1% vs. 39.3% in cycle 
3 and 55% vs. 38.4% in cycle 4 for a cumulative percentage 
improvement (p=0.017) (Herrstedt et al 2005).
Doxorubicin and cyclophosphamide were also given 
with cisplatin to 80 patients on the control arm and 81 on the 
aprepitant arm of the two large studies reported above, testing 
the efﬁ  cacy of adding aprepitant to antiemetic regimens in 
patients receiving cisplatin. The improvement seen by adding 
aprepitant was greater in the arms where doxorubicin and 
cyclophosphamide were added to cisplatin than when the 
combination included other agents, with a 33% improvement 
compared with 20% for the whole study population (Gralla 
et al 2005). 
Tolerability and quality of life
Aprepitant is very well tolerated. The beneﬁ  t in the two large 
trials of adding aprepitant to ondansetron and dexamethasone 
for cisplatin-induced emesis was seen with only small 
differences in side-effects between the two arms of the 
study (Hesketh et al 2003; Poli-Bigelli et al 2003). The most 
common additional reports with the aprepitant combination 
were hiccups (4.6%), asthenia/fatigue (2.9%), constipation 
(2.2%), headache (2.2%), anorexia (2.0%), and increased 
ALT (2.8%). The only appreciable difference in tolerability 
in the doxorubicin and cyclophosphamide trial was a higher 
rate of constipation in patients on the active control regimen 
(18.0% vs 12.3%) but more dyspepsia in those on the 
aprepitant regimen (8.4% vs 4.9%) (Warr et al 2005).
Chemotherapy-induced emesis is associated with a 
signiﬁ  cant deterioration in global quality of life (Osoba 
et al 1997). Patients who have nausea and vomiting report 
experiencing more fatigue, anorexia, and insomnia. 
Controlling nausea and vomiting has been found to more 
globally affect a patient’s quality of life. To measure the International Journal of Nanomedicine 2007:2(1) 17
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impact of the control of emesis on quality of life, the 
Functional Living Index Emesis (FLIE) was used in the 
above studies. Logistic regression analysis showed that 
more patients in the aprepitant groups reported minimal 
or no impact of chemotherapy-induced emesis on daily 
life compared with those on just a 5HT3 antagonist and 
dexamethasone (74.7% vs 63.5% in the South American 
study, 70.4% vs 64.3% in the international study). In the Warr 
et al study more patients on aprepitant reported minimal or 
no impact of CINV on daily life, as measured by the FLIE 
questionnaire (63.5% v 55.6%; p= 0.019).
Drug interactions
Aprepitant is primarily metabolized by the p-450 isoenzyme 
CYP3A4 cytochrome system and therefore has the potential 
to interact with a range of other drugs (Sanchez et al 2005). 
The metabolic proﬁ  le of aprepitant over a 2-week period of 
time can be described as an inhibitor, then an inducer, and 
then no effect on CYP3A4 after 2 weeks (Shadle et al 2004). 
Of relevance is the interaction with dexamethasone which 
doubles the plasma concentration of the steroids (McCrea 
et al 2003). This is why the doses of dexamethasone in 
the large cisplatin trials were decreased in the aprepitant 
arms so the plasma concentrations would be equivalent in 
both arms of the studies. Interactions are more likely with 
co-administered oral medications. No interactions with 
ondansetron or palonosetron have been recorded (Blum et 
al 2003; Shah et al 2005). In the limited studies of possible 
interactions with cytotoxics, no interactions have been found 
with docetaxel and
 there was no obvious problem with the 
seven different drugs co-administered with cisplatin in the 
two large cisplatin trials (Nygren et al 2005). In a small study, 
aprepitant inhibited both cyclophosphamide and thiotepa 
metabolism, but the effects of these interactions was small 
compared with the total variability (de Jong et al 2005). 
More data are needed studying possible interactions with oral 
cytotoxics. There is a decrease in the concentration of co-
administered ethinyl oestradiol in studies of long-term use, 
so patients are advised to use additional barrier contraceptive 
methods (Olver 2004). A signiﬁ  cant induction of CYP2C9 
metabolism of warfarin by aprepitant has been found which 
necessitates close monitoring of clotting studies in the 7–10 
days after aprepitant (Depre et al 2005).
Guidelines
These results have led the Multinational Association for 
Symptom Control in Cancer to recommend that the triple 
drug regimen of a 5HT3 receptor antagonist, dexamethasone, 
and aprepitant be used to prevent acute emesis from 
chemotherapy with high emetic potential, and then to 
continue with aprepitant and dexamethasone on days 2 and 
3 to prevent delayed emesis (The Antiemetic Subcommittee 
MASCC 2006). With anthracycline and cyclophosphamide 
combinations the same recommendation is made with the 
three drugs on day 1 to prevent acute emesis with aprepitant 
or dexamethasone to prevent delayed emesis.
Conclusions
Having made a major advance in the control of acute post-
chemotherapy emesis with the introduction of the 5HT3 
receptor antagonists in combination with dexamethasone, 
adding the oral NK1 receptor antagonist aprepitant improves 
the control of the acute phase of emesis, but also has a 
particular impact on the control of delayed emesis. In 
practice, patients receiving chemotherapy of high emetic 
potential are best treated prophylactically with the three 
drugs to control the acute phase and then two further days 
of aprepitant with dexamethasone for the delayed phase. 
Similar recommendations can be applied to patients receiving 
chemotherapy of moderate emetic potential. The addition 
of aprepitant adds little to the toxicity of the antiemetic 
combination and not only improves the control of emesis, but 
in turn improves the quality of life of the patients receiving 
chemotherapy.
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